Scroll back to top

VistaSeq Endocrine Cancer Panel

CPT: Call client services


Familial Cancer testing, Hereditary Cancer testing, Inherited Cancer testing

Test Includes

Genes tested in this panel include CDC73, MAX, MEN1, NF1, PRKAR1A, PTEN, RET, SDHB, SDHC, SDHD, TMEM127, TP53 and VHL.

Special Instructions

A clinical questionnaire should be submitted with all specimens

Expected Turnaround Time

24 - 28 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Specimen Requirements


Whole blood, saliva collected in an Oragene Dx collection kit


10 mL whole blood, 2 mL saliva

Minimum Volume

7 mL whole blood, 0.5 mL saliva


Lavender-top (EDTA) tube or yellow-top (ACD) tube


Blood is collected by routine phlebotomy. Saliva is collected by spitting into the provided container until it reaches the fill line.

Storage Instructions

Room temperature

Causes for Rejection

Frozen or hemolyzed specimen; quantity not sufficient for analysis

Test Details


This assay is intended for patients with a family history consistent with an inherited cancer syndrome.


This assay is not designed to detect deep intronic variants, balanced translocations, large inversions, mosaicism or complex genomic rearrangements. Homopolymer regions and rare polymorphisms under primer sites can affect the performance of the assay. The presence of pseudogenes can interfere with the ability to detect variants in certain genes. This assay is not intended for use in patients who have received allogeneic bone marrow transplants, as it may not reflect the germline genetic status of these patients. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).


The entire coding region of a panel of genes related to hereditary cancer is examined by next generation sequencing analysis. Additionally, portions of the flanking noncoding regions are also examined. Comprehensive deletion/ duplication testing is performed using microarray CGH for 13 genes. Genes tested in this panel include CDC73, MAX, MEN1, NF1, PRKAR1A, PTEN, RET, SDHB, SDHC, SDHD, TMEM127, TP53 and VHL. Clinically significant findings are confirmed by Sanger sequencing or qPCR. Results are reported using ACMG guidelines and nomenclature recommended by the Human Genome Variation Society (HGVS).